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Abstract. In this randomized, double-blinded Phase 2 trial, 30 patients with Leishmania panamensis cutaneous
leishmaniasis were randomly allocated (1:1) to receive once daily topical treatment with WR 279,396 (15% paromomycin +
0.5% gentamicin) or Paromomycin Alone (15% paromomycin) for 20 days. The index lesion cure rate after 6 months
follow-up was 13 of 15 (87%) for WR 279,396 and 9 of 15 (60%) for Paromomycin Alone (P = 0.099). When all treated
lesions were included, the final cure rate for WR 279,398-treated patients was again 87%, but the final cure rate for
Paromomycin Alone-treated patients was 8 of 15 (53.3%; P = 0.046). Both creams were well tolerated with mild application
site reactions being the most frequent adverse event. The increased final cure rate in the WR 279,396 group in this small
Phase 2 study suggests that the combination product may provide greater clinical benefit than paromomycin monotherapy
against L. panamensis cutaneous leishmaniasis.
INTRODUCTION
Leishmania infection is endemic in 98 countries or territories,
with more than 350 million people at risk. Published figures
indicate an estimated incidence of 2 million new cases per year
(0.5 million visceral leishmaniasis [VL] and 1.5 million of cuta-
neous leishmaniasis [CL]).1 In the United States (U.S.), CL has
been reported in southern Texas along theMexican border2 and
in travelers returning from endemic areas.3 In the U.S. Military
over 2,878 cases of CL has been parasitologically confirmed
since April 2003 at the Leishmania Diagnostics Laboratory
at the Walter Reed Army Institute for Research. Although CL
ultimately self-cures, the infection can create substantial mor-
bidity caused by the continued presence of a skin ulcer and the
psychological impact of disfigurement4; there is no U.S. Food
and Drug Administration (FDA) approved drug for CL in the
United States, no available vaccines, and no chemoprophylaxis.
Several antileishmanial chemotherapeutic agents have been
developed and evaluated for the treatment of VL,5 a life-
threatening disease where the need for systemic therapy is
compelling.6 An inherent difficulty with using anti-VL drugs
for CL is that benefit may easily outweigh the toxicity of sys-
temic agents for a fatal disease such as VL, but such toxicity
may be harder to justify for a non-fatal disease such as CL.6 As
a result, treatment of CL is unsatisfactory and is currently
the major unmet medical need for the leishmaniases.
A new approach for CL treatment favored by the World
Health Organization (WHO) and other experts is the use of a
local treatment followed by parenteral treatment only if the
local treatment fails or cannot be performed.7,8 This step-wise
approach is intended to limit the risk of severe adverse events,
increase compliance, facilitate CL treatment, and reduce cost
while preserving efficacy. One prominent non-systemic treat-
ment is the topical application of paromomycin-containing
creams. To create a paromomycin cream that would be simul-
taneously effective, well tolerated, and improve healing, we
developed a cream (WR 279,396) containing paromomycin
sulfate 15% plus gentamicin sulfate 0.5% in a complex base to
aid drug penetration. Gentamicin was included in the formula-
tion because gentamicin augmented the effect of paromomycin
in mouse models of CL, particularly against the New World
species, Leishmania panamensis and Leishmania amazonensis.9
In a Phase 2 clinical trial in Tunisia,10 WR 279,396 was signifi-
cantly more effective than vehicle control versus Leishmania
major at the same study site at which a WHO topical formula-
tion (paromomycin without gentamicin) was ineffective.11
In the course of developing WR 279,396, two studies of the
pharmacokinetics (PKs) of this combination formulation and
of Paromomycin Alone in the same complex base were
performed in CL patients in Panama and Peru. The combined
PK data from both sites is being reported in a separate publi-
cation (accepted for publication). Efficacy and safety data
were secondary endpoints in these studies. Here, we report
the efficacy and safety of WR 279,396 compared with
Paromomycin Alone against CL in the Panama study.
METHODS
Ethics. The study was sponsored by the Office of the Sur-
geon General, Department of the Army, USA, and it is regis-
tered with ClinicalTrials.gov identifier NCT 01083576. The
protocol was approved by the Panamanian National Commit-
tee of Bioethics for Research, Panama City, Panama, and by
the Human Research Protections Office, U.S. Army Medical
Research and Materiel Command, Ft. Detrick, Maryland.
The study complied with all applicable laws, rules, and regu-
lations of the United States and Panama, and it was conducted
in accordance with the International Conference on Harmoni-
zation Good Clinical Practice Guidelines, the Belmont Princi-
ples, and the ethical principles that have their origins in the
Declaration of Helsinki. The investigators adhered to the poli-
cies for protection of human subjects as prescribed in U.S.
Army Regulation 70-25. Informed consent was obtained from
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all study participants and/or guardians before enrollment.
Minors also provided assent.
Study patients. Eligible patients were males or non-pregnant/
non-lactating females; ³ 5 years of age; with £ 10 lesions; and
with one of these lesions (the index lesion) having the following
characteristics: ulcerative, at least 1 cm, and < 5 cm in greatest
diameter of lesion, including induration, and confirmed to con-
tain Leishmania by culture or microscopic examination of lesion
material. The reason to designate one lesion as the index lesion
is that the response of at least that lesion would reflect the
efficacy of treatment on an ulcer known to be caused by Leish-
mania. Subjects could not have signs of disseminated disease,
against which a topical treatment would not be expected to be
effective or recent treatment (within 8 weeks of starting study
treatments) with a recognized antileishmanial, and were gener-
ally healthy otherwise.
Sample size.As the study was primarily a PK evaluation that
was not designed to compare the efficacy of the two topical
creams, the selection of the number of subjects (15 in each
arm) was based on the following objectives: 1) to obtain PK
data which, when combined with PK data from a similarly
designed Phase 2 study in Peru, would provide a collective
body of data to determine the extent of systemic drug expo-
sure; and, 2) to obtain sufficient data to have a preliminary
estimation of the initial clinical cure rate as a basis for calculat-
ing sample sizes for a possible larger trial.
Study design. This was a randomized, double-blinded,
parallel-group study in which the PKs, efficacy, and safety of
WR 279,396 and Paromomycin Alone creams were compared
for the treatment of L. panamensis CL in Panama. After estab-
lishing eligibility for the study, a total of 30 patients were ran-
domly assigned in 1:1 allocation to the two treatment groups
in a blinded manner. To balance treatment assignments by age
group, a permuted block randomization method was used to
generate the treatment randomization within age groups. Sub-
jects were stratified by age group: 5–11 years, 12–7 years, and
³ 18 years of age. No more than 18 subjects could be random-
ized in any age range, so that there would be at least six subjects
in each age stratum evaluable for the PK analysis.
Subjects were treated once daily for 20 days with the topical
creams. Blood samples for PKs were collected during the first
20 days, local application site toxicity was assessed daily, and
lesion sizes were measured five times during the treatment
period. Subjects were followed at weekly intervals after
completing treatment of safety and efficacy up to Day 63,
and then had final follow-up visits at Days 100 and 168.
Study area. This study was conducted between 16 February
2010 and 28 March 2011 on patients recruited from the
area surrounding Panama City, Panama, where L. panamensis
is prevalent.
Parasitology. Lesion samples were obtained from ulcera-
tive lesions by scraping and aspiration at baseline and 1 day
after the end of therapy on Day 21. Specimens were smeared
onto microscope slides, placed in culture medium, and ana-
lyzed at the Parasitology Laboratory of the Instituto
Conmemorativo Gorgas de Estudios de la Salud (ICGES),
Panama´ City, Panama´. At the ICGES, proof of infection
caused by leishmaniasis was documented through 1) the
microscopic identification of Leishmania amastigotes by
Giemsa staining of specimen slides; and/or 2) by the demon-
stration of motile Leishmania promastigotes in aspirate cul-
tures. Whenever possible, Leishmania species identification
(speciation) was also performed using polymerase chain reac-
tion (PCR) analysis or isoenzyme analysis. For PCR, a sample
of lesion scrapings from each subject was sent to the ICGES
Parasitology Laboratory for analysis12,13; for isoenzyme anal-
ysis, only samples of cultures that were positive at the ICGES
were sent for isoenzyme analysis14 to the Leishmania Diag-
nostics Laboratory, Walter Reed Army Institute of Research,
Silver Spring, MD.
Drug administration. WR 279,396 and Paromomycin Alone
creams were manufactured by Teva Pharmaceuticals USA,
Sellersville, PA, in accordance with Good Manufacturing Prac-
tice. For each patient, all lesions (i.e., the index lesion plus
any non-index lesions) were treated topically once daily for
20 days. Before the first application, the lesions were cleaned
with soap and water, debrided, and then dried. At each subse-
quent application of the investigational creams, the previous
day’s application and dressing were removed, the lesion sites
were cleaned with soap, water, and sterile 0.9% saline, and
then dried using sterile cotton gauze sponges, and redressed.
A generous amount of cream was applied to each lesion by
rubbing the cream into the lesion for about one minute before
applying the dressing.
Study procedures. Medical history, physical exam, vital
signs, parasitology, and baseline clinical laboratory measure-
ments (alanine aminotransferase, aspartate aminotransferase,
glucose, sodium, potassium, creatinine, white blood cells,
hemoglobin, and platelet count) were performed to establish
patient eligibility for inclusion in the study. Females of child-
bearing potential had a pregnancy test. Serum creatinine was
repeated at the end of treatment (Day 20), and parasitology
was also repeated one day after completing treatment (Day 21).
Adverse events were assessed at every visit during the
study. Lesionmeasurements and vital signs were taken before
treatment, five times during treatment, and at all follow-up
visits. Lesions were photographed before treatment and at
all follow-up visits.
Follow-up and toxicity evaluation. Efficacy was assessed by
measuring the CL lesion area (calculated according to the
formula for an ellipse) at baseline, at the end of therapy on
Day 20, and at follow-up on Days 28, 35, 42, 49, 56, 63, 100,
and 168 (end of study). Application sites (CL lesions and
surrounding area) were inspected daily during treatment
of erythema and edema/swelling and any other clinical signs,
and the patient was asked about pain using the Wong-Baker
FACES pain rating scale.15 General questions about adverse
events were also asked at each visit. Medications to treat side
effects were recorded. Serum creatinine was measured at
Day 20 to assess potential aminoglycoside-related renal toxicity.
Clinical endpoints criteria. Final clinical cure was defined
as (A and C) or (B and C), where A = patient had initial
clinical cure (100% re-epithelialization of index lesion by
nominal Day 63); B = patient had initial clinical improvement
(> 50% re-epithelialization of index lesion by nominal Day 63
followed by 100% re-epithelialization of the index lesion
on or before nominal Day 100; and C = patient had no relapse
of index lesion. Relapse was defined as an index lesion meeting
the criteria for initial clinical cure or initial clinical improve-
ment that had any new ulceration (> 0 + 0 mm measurement)
by nominal Day 168.
The protocol-specified primary efficacy endpoint was the
number of subjects with an index lesion that exhibited final
clinical cure. If the subject was withdrawn early from the
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study, this subject was then considered a treatment failure.
The occurrence of new lesions was not considered a treatment
failure, as the investigational drugs were administered directly
to the lesion and no systemic effects were expected. Secondary
endpoints included number of subjects where all baseline
lesions that received treatment met the definition for final clin-
ical cure and all lesions treated independently of the subject.
The safety endpoints were adverse events in general, appli-
cation site reactions, and aminoglycoside renal toxicity deter-
mined by serum creatinine measurements at the end of therapy
on Day 20.
Statistical analysis. Statistical analyses were performed using
SAS software, version 9.2 (SAS Institute, Inc., Cary, NC). The
modified intention-to-treat (mITT) population, which included
all randomized subjects who received at least one application
of a study drug, was used for efficacy and safety analyses.
There were no formal hypotheses tested with respect to
efficacy endpoints as the study was primarily a PK evaluation.
It was not designed to compare the efficacy of the two topical
creams, but rather to collect data to support the design of a
possible Phase 3 trial. However, exploratory analyses were
performed on efficacy endpoints to determine if the observed
differences in the two study groups were statistically signifi-
cant. The null hypothesis was that there was no difference
in the primary and secondary efficacy endpoints between the
2 study groups. Final clinical cure rates were compared
between the two study groups by two-sided uncorrected c2
analysis.16 Although the sample size in this study was small
(30 total subjects), as this study was “One Margin Fixed
Design,” the c2 analysis was considered more appropriate
than the more conservative Fisher’s exact test to explore the
clinical endpoints.17 Baseline variables were explored statisti-
cally to identify differences that might have an impact on out-
comes to be considered in possible future study designs.
RESULTS
Of the 54 patients who were screened, 30 were eligible for the
study and were randomized equally between the two treatment
groups (Figure 1). Of the 24 subjects not eligible to participate
in the study, 10 had lesions that were parasitologically negative,
5 had a single lesion that was < 1 cm, 2 had a single lesion
> 5 cm, 2 had > 10 lesions, 2 had started antimonial therapy,
1 did not have an ulcerated lesion, and 2 started screening but
recruitment ended. Six subjects in the Paromomycin Alone
group and one subject in the WR 279,396 group were with-
drawn from the study by the investigator before the final visit
at Day 168 because of treatment failure. All of these subjects
were included in the mITT analysis.
Most patients (80%) were male (Table 1). There were
17 adults, 7 patients aged 12–17 years, and 6 patients aged
5–11 years. There were a total of 64 lesions on the 30 patients,
with most patients having two lesions; the index lesion and
one other. Because index lesions were ulcerative by protocol,
the majority of lesions were ulcerative. The mean lesion area
was ~175 mm2, although lesions ranged in area between 2 and
839 mm2. Forty-seven percent of parasites in index lesions were
positive by culture and were speciated; all were L. panamensis.
All but one subject received 20 days of daily drug application.
One subject in the WR 279,396 group missed the Day 3 visit,
but received the rest of the scheduled treatments.
Efficacy. For the patients in the WR 279,396 group, the index
lesion final clinical cure rate was 13 of 15 (87%) (Table 2). The
all-lesions-per-patient cure rate was also 13 of 15 (87%).
Figure 1. Subject disposition. A total of 54 subjects were consented and screened of which 30 were randomized. All but one of the 30 subjects
received 20 days application of study drug. One subject missed one day. Subjects who were withdrawn early from the study were withdrawn by
the investigator as judged to be treatment failures: one subject in the WR 279,396 group and six subjects in the Paromomycin Alone group.
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Because there were a total of 34 presenting lesions of which
32 cured, the per-lesion cure rate was 94%. For the two patients
in the WR 279,396 group whose index lesions did not meet the
protocol criteria for cure, one index lesion failed because it
never re-epithelialized and one index lesion failed because of
relapse. All non-index lesions on these patients also cured. The
typical response of a lesion to treatment is shown in Figure 2.
For the patients in the Paromomycin Alone group, the index
lesion final clinical cure rate was 9 of 15 (60%, P = 0.099 versus
the WR 279,396 group) (Table 2). The all-lesions-per-subject
cure rate was 8 of 15 (53.3%, P = 0.046 versus the WR 279,396
group). Because there were a total of 30 presenting lesions of
which 20 cured, the per-lesion cure rate was 66.7% (P = 0.005
versus the WR 279,396 group). For the six patients in the
Paromomycin Alone group whose index lesions did not show
a final clinical cure, one patient was removed by the investiga-
tor on Day 35 because the lesion had doubled in size (Table 2),
one failed to show at least 50% re-epithelialization on
Day 63, and two had not 100% re-epithelialized on Day 100.
For the remaining two who did not cure, the index lesion
re-epithelialized on Day 63, but had evidence of infiltration
at that time, presumably caused by continued parasitic infec-
tion. One patient also had a non-index lesion that did not meet
the protocol defined criteria for cure.
In addition, although this did not contribute to the failure
rate, a new cutaneous lesion arose on two subjects (one sub-
ject in each of the two study groups). These new lesions were
treated for 20 days with the same treatment to which each
subject had been randomized. Both new lesions cured.
When repeat parasitological testing was performed on Study
Day 21 (1 day after treatment completion), 15 of 15 (100%) of
index lesions in theWR279,396 groupwerenegative for parasites
Table 1
Baseline characteristics of 30 subjects with cutaneous leishmaniasis
(CL) enrolled in the study
Characteristics
WR 279,396
(N = 15)
Paromomycin
alone (N = 15)
Sex: N male (%) 11 (73) 13 (87)
Age: mean (SD) 25 (16) 24 (16)
Adults: N 9 8
Children (12–17 yr): N 3 4
Children (5–11 yr): N 3 3
Total number of lesions: N 34 30
Ulcerated lesions: N 25 28
Non-ulcerated lesions: N 9 2
Number of Lesions per
subject: mean (SD)
2.3 (1.7) 2.0 (1.0)
Area of all lesions (mm2):
mean (SD)
149 (202) 181 (207)
Area of index lesion (mm2):
mean (SD)
165 (152) 215 (220)
Duration of disease before
treatment (days): mean (SD)
94 (97) 68 (18)
Diagnosis of index lesion
Microscopy: N positive/N tested (%) 14/15 (93) 15/15 (100)
Culture: N positive/N tested (%) 7/13 (54) 12/13 (92)
Speciation by isoenzyme:
N positive for Leishmania
panamensis/N tested (%)
3/13 (23%) 11/13 (85%)
Table 2
Summary of efficacy endpoints
Endpoint WR 279,396
Paromomycin
alone c2 P value
Subjects with final clinical
cure of the index lesion,
N (%)
13/15 (86.7)* 9/15 (60.0)† 0.099
Subjects with final clinical
cure of all lesions, N (%)
13/15 (86.7) 8/15 (53.3) 0.046
Final cure rate by–all lesions,
n (%)
32/34 (94.1) 20/30 (66.7) 0.005
*One index lesion failed because it never re-epithelialized and one index lesion failed
because of relapse.
†Four index lesions did not meet efficacy criteria for lesion re-epithelialization at desig-
nated time points: one on Day 63, two on Day 100, and one patient was removed by the
investigator on Day 35 because the lesion had doubled in size. For two other patients,
the index lesion re-epithelialized on Day 63, but had evidence of infiltration at that time
presumably caused by continued parasitic infection.
Figure 2. Example of response to treatment with WR 279,396.
The subject presented with a deep ulcerous lesion surrounded by a
large area of induration on the foot. At 1 week after completing
treatment (Day 28), the induration had resolved and the ulcer was
nearly completely cured. The ulcer completely cured by Day 42 and
remained cured for the duration of follow-up.
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by both smear and culture examination. In the Paromomycin
Alone group, 13 of 14 (92.9%)were negative.
For index lesions that cured, median time to cure was
almost identical in the two treatment groups: 49 days for the
WR 279,396 group and 48 days for the Paromomycin Alone
group (Figure 3).
Two adult subjects, one in each of the two treatment groups,
developed erythema secondary to an erosive lesion in the nostril
and turbinate during the trial; both were grade 1 (mild). In the
first subject, an erosive lesion in the left nostril was observed
at Study Day 62 and a second lesion was observed at Day 132.
In the second subject, an erosive lesion was observed in the right
inferior turbinate at Day 63. These lesions were biopsied
for pathology, culture, and PCR. Although no lesion showed
evidence of Leishmania parasites by microscopy or culture,
lesions from both patients were positive by PCR. Both sub-
jects were removed from the study (therefore they were con-
sidered treatment failures) and were treated with meglumine
antimoniate off-study.
Safety. For both treatment groups, essentially all patients
had mild adverse events and less than half of the patients
had moderate adverse events (Table 3).
The one severe adverse event was a migraine headache
in the WR 279,396 group that was not considered to be drug
related. The most frequently observed treatment-related
adverse events were application site reactions, with edema
being reported in 13.3% of subjects in the WR 279,396 group
and 20% in the Paromomycin Alone group. Erythema was
reported in 20.0% of subjects in the WR 279,396 group and
13.3% in the Paromomycin Alone group. Application site
pain was noted more frequently in the Paromomycin Alone
group (33.3%) than in the WR 279,396 group (6.7%). Contact
dermatitis reactions (caused by the gauze and tape of the
dressing) occurred in roughly the same number of subjects
in both groups, 6 (40.0%) for the WR 279,396 group and
8 (53.3%) for the Paromomycin Alone group.
DISCUSSION
Two topical antileishmanial formulations, WR 279,396
(paromomycin 15% plus gentamicin 0.5%) in a complex
cream base, and Paromomycin Alone (15% paromomycin
in the same complex cream base, were each administered
to 15 subjects with uncomplicated CL in Panama. The index
lesion (the lesion confirmed to be caused by Leishmania) and
all other lesions were treated once daily for 20 days. Although
the primary purpose of this trial was PKs, the need to provide
effective, well-tolerated treatment of New World CL makes
the efficacy and safety data also of interest.
The protocol-defined primary efficacy endpoint was final clin-
ical cure of the index lesion (at least 50% reduction in the index
lesion area byDay 63, continued or complete re-epithelialization
by Day 100, and no relapse by the end of the trial on Day 168).
This compound definition is in accord with clinical practice.
Treatment of New World CL is viewed as failing if the lesion
is not appreciably smaller at early time points and not
completely healed at 6 months7; the cure rates for all of the
clinical endpoints were greater in the WR 279,396 group than
the Paromomycin Alone group. As expected from a topical
formulation, there were no systemic toxicities, and drug-related
adverse events were limited to application site reactions.
Hypersensitivity reactions were also observed. These were
attributed to the tape that had been used in the dressings
overlying treatment application sites.
Figure 3. Mean percentage cure rate over time for the index lesion. Index lesions start to completely re-epithelialize at Day 28 and continue
to heal until about Day 100 after which time, if subjects had a lesion that did not cure; the subject was taken off study and offered other treatment.
At Day 49 the curves for the two treatment groups start to separate with lesions treated with WR 279,396 ultimately reaching a higher final cure
rate than that for the Paromomycin Alone group.
Table 3
Adverse events
WR 279,396
(N = 15)
Paromomycin
(N = 15)
Summary of overall adverse events - total number (%) of subjects:
Mild 15 (100) 14 (93)
Moderate 6 (40) 4 (27)
Severe 1 (7) 0 (0)
Summary of application site reactions - total number (%) of subjects:
Application site erythema 3 (20) 2 (13)
Application site edema 2 (13) 3 (20)
Application site pain 1 (7) 5 (33)
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Topical treatment with WR 279,396 can be compared with
topical treatment with Paromomycin Alone in this study,
to topical treatment with paromomycin 15% plus methylben-
zethonium chloride (MBCL) 12% in the literature, and to
treatment with vehicle/no treatment in the literature. In this
study, WR 279,396 trended toward superiority versus
Paromomycin Alone on the basis of the index lesion cure rate,
and was statistically superior to Paromomycin Alone on the
basis of per patient and per-lesion cure rate. Although the
gentamicin component that differentiates WR 279,396 from
Paromomycin Alone is not known as an antileishmanial
agent, Daneshvar and others18–20 succeeded in producing
attenuated Leishmania by culturing promastigotes under
pressure of gentamicin. Promastigotes of the attenuated lines
could enter but not survive in macrophages derived from
murine bone marrow, and mice inoculated subcutaneously
with attenuated parasites did not develop CL skin lesions.
In lesions treated with WR 279,396, it may be that parasites’
constant exposure to the gentamicin component of WR
279,396 leads to their attenuation, thereby increasing their
vulnerability to both paromomycin treatment, and host
immune mechanisms.
Paromomycin 15% plus MBCL 12% has not been evaluated
alone against L. panamensis. However, the combination of
this topical formulation with short courses of parenteral anti-
mony was tested in anL. panamensis-endemic area of Colombia,
and it did not augment the cure rate compared with short
courses of antimony alone.21 In contrast, Paromomycin 15%
plus MBCL 12% was tested in Guatemala (infecting species
L. braziliensis and L. mexicana), where it was very effective
(86% of patients were cured) compared with vehicle control
(39% of patients were cured).22
The mITT and per protocol cure rates for this formal
study were identical, and can be compared with the per
protocol cure rate for L. panamensis treated with placebo/
no-treatment in investigator-initiated studies. The WR 279,396
cure rate in this study was considerably higher than published
placebo/no-treatment cure rates of 33–36% reported for
L. panamensis in Colombia.23,24 The index lesion cure rate
of 87% for WR 279,396 also compares favorably with cure
rates after treatment with the antimonial Glucantime for
L. panamensis in Colombia of 36–81% in three different
studies after the same 6-month follow-up period.24–26 How-
ever, the cure rate of WR279,396 in L. panamensis observed
in this study will be confirmed in a Phase 3 study (N = 300),
planned to start in Panama in Spring 2013.
Topical treatments are being developed for uncomplicated
CL where the less tolerable systemic antileishmanial thera-
pies may not have an acceptable benefit-risk profile. Patients
with uncomplicated CL present with diagnostically confirmed
CL, but lesion location and infecting Leishmania species are
such that the parasite has little or no potential to disseminate
to the mucosal tissue or elsewhere. Entry criteria for patients
in our studies of WR 279,396 include patients with < 10 lesions
and no evidence of systemic dissemination to mucosal tissue
by qualified physician examination.
Compared with systemic treatments, important advantages
of all topical or local treatments for CL are 1) their failure
to generate clinically meaningful systemic drug exposure, and
2) their relatively low risk for systemic side effects. Topical
or local interventions may, however, generate considerable
application site reactions, depending on the formulation.
For example, topical paromomycin 15%formulatedwithMBCL
12% causes unacceptable stinging27; intralesional injections of
antimony are painful28 and particularly problematic for chil-
dren and patients with facial lesions; the ThermoMed device
requires anesthetics to dull the blistering pain that results
from intense heating of the skin29; and cryotherapy creates
edema and bullae, which necessitate 1–2 weeks of saline com-
presses and antibiotic creams.29 In contrast, bothWR 279,396
and Paromomycin Alone were formulated to promote drug
penetration into the dermis while avoiding substantial local
toxicity. With WR 279,396, any application site reactions
are typically mild and have yet to cause a patient to withdraw
from treatment.
In conclusion, new topical therapies containing paromomycin
with or without gentamicin may offer an effective low toxicity
alternative to the current standard of care pentavalent antimo-
nials for the treatment of uncomplicated CL in Panama.
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